Skip to main content
. 2007 Jan 23;96(2):321–328. doi: 10.1038/sj.bjc.6603543

Figure 3.

Figure 3

Immunohistochemistry (IHC) for ERBB2 and AKT in matched primary cervical tumours and LN micrometastases. Quantitative analysis of IHC-positive cells revealed that ERBB2 showed a significant stronger expression in the primary tumour (P=0.0006), whereas AKT showed a significant stronger expression in the LN metastases (P=0.0064).

HHS Vulnerability Disclosure